CD274 and non-small cell lung carcinoma: In addition, the treatment of NSCLC patients was also divided into 3 categories based on the gene test results as follows: 1, targeted therapy for patients with gene mutation; 2, immunotherapy for patients with PDL1 ≥ 50% (positive); and 3, patients who did not benefit from targeted and immunotherapy and were returned to traditional radiotherapy and chemotherapy.